- Care missions: – Provide diagnosis of motoneuron diseases – Conduct multidisciplinary evaluation every 3 monthsProvide medical and social support – Organize home support
- Training missions: – Organize training actions for the medical and paramedical staff – Share specific knowledges on ALS patient’s care – Participate in and get involved in working groups during the coordination symposium of French ALS centres
- Research missions: – Ensure clinical research activities through the establishment of internal and multicenter research protocols: area of research: epidemiology, cognition and nutrition – Participate in therapeutic research in collaboration with the pharmaceutical industry – Communicate the results of research through oral or displayed communications – Publish the results of research into national and international levels.
| ALS Centre CHU Dupuytren | |
|---|---|
| Foundation year | 2003 |
| Director | Prof. Philippe Couratier |
| Principal investigator | Prof. Philippe Couratier |
| Contact information | |
|---|---|
| Address | ALS Centre CHU Dupuytren |
| Contact | Prof. Philippe Couratier |
| Phone | +33(0)5.55.05.65.59 |
| philippe.couratier@unilim.fr | |
Publications
- Validity of medico-administrative data related to amyotrophic lateral sclerosis in France: A population-based study. Vasta R, Boumédiene F, Couratier P, Nicol M, Nicoletti A, Preux PM, Marin B; Fralim Consortium.. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):24-31.
- Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial. Gonzalez-Bermejo J, Morélot-Panzini C, Tanguy ML, Meininger V, Pradat PF, Lenglet T, Bruneteau G, Forestier NL, Couratier P, Guy N, Desnuelle C, Prigent H, Perrin C, Attali V, Fargeot C, Nierat MC, Royer C, Ménégaux F, Salachas F, Similowski T. Lancet Neurol. 2016 Nov;15(12):1217-1227. doi: 10.1016/S1474-4422(16)30233-2.
- Semantic and nonfluent aphasic variants, secondarily associated with amyotrophic lateral sclerosis, are predominant frontotemporal lobar degeneration phenotypes in TBK1 carriers. Caroppo P, Camuzat A, De Septenville A, Couratier P, Lacomblez L, Auriacombe S, Flabeau O, Jornéa L, Blanc F, Sellal F, Cretin B, Meininger V, Fleury MC, Couarch P, Dubois B, Brice A, Le Ber I. Alzheimers Dement (Amst). 2015 Oct 30;1(4):481-6.
- Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Marin B, Boumédiene F, Logroscino G, Couratier P, Babron MC, Leutenegger AL, Copetti M, Preux PM, Beghi E. Int J Epidemiol. 2016 May 16.
- Population-Based Evidence that Survival in Amyotrophic Lateral Sclerosis is Related to Weight Loss at Diagnosis. Marin B, Arcuti S, Jesus P, Logroscino G, Copetti M, Fontana A, Nicol M, Raymondeau M, Desport JC, Preux PM, Couratier P; French register of ALS in Limousin (FRALim). Neurodegener Dis. 2016;16(3-4):225-34.
Restricted information
| Serving population | |
|---|---|
| Serving population | 1.200.000 |
| Patient resources | |
|---|---|
| Population based register | Yes |
| Clinic based register | Yes |
| Geographically matched controls | No |
| Number of muscle samples | 10 |
| Number of skin samples | 20 |
| Number of brain samples | 10 |
Banks
| Type | ALS Patients | Controls | Other |
|---|---|---|---|
| DNA bank | 100 | 0 | 100 |
| Serum bank | 100 | 100 | 100 |
| RNA bank | 0 | 0 | 0 |
| Research activities | |
|---|---|
| Clinical management research | Yes |
| Neuro epidemiology | Yes |
| Neuro physiology | No |
| Neuro imaging | No |
| Neuro psychology | Yes |
| Neuro pathology | Yes |
| Genomics | No |
| Transcriptomics | No |
| Metabolomics | Yes |
Clinical Trials - Industry sponsored
| Name | Type | Patients |
|---|---|---|
| ONO (2007-2009) | ONO (2007-2009) | 15 |
| TROPHOS (2009-2012) | TROPHOS (2009-2012) | 36 |
| TROPHOS Open Labelled (2010-2013) | TROPHOS Open Labelled (2010-2013) | 14 |
| GSK (2013-2015) | GSK (2013-2015) | 7 |
| Cytokinetics Phase II (2013-2014) | Cytokinetics Phase II (2013-2014) | 4 |
| Cytokinetics Phase III (2016-ongoing) | Cytokinetics Phase III (2016-ongoing) | 5 |
Clinical Trials - Investigator initiated
| Name | Type | Patients |
|---|---|---|
| EURECALS (2009-2013) | EURECALS (2009-2013) | 100 |
| BMAALS (2012-2015) | BMAALS (2012-2015) | 1199 |
| NUTRALS (2014-ongoing) | NUTRALS (2014-ongoing) | 24 |